While EGFR-TKI significantly prolong OS in advanced NSCLC patients, real-world clinical evidence demonstrated considerable individual variability in both therapeutic efficacy and safety signals (Riely et al., 2009; Gainor and Shaw, 2013). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.